Medtronic PLC (MDT)vsNeuropace Inc (NPCE)
MDT
Medtronic PLC
$94.78
+2.46%
HEALTHCARE · Cap: $121.20B
NPCE
Neuropace Inc
$12.93
-0.69%
HEALTHCARE · Cap: $443.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 34988% more annual revenue ($37.54B vs $106.99M). MDT leads profitability with a 13.9% profit margin vs -17.9%. MDT earns a higher WallStSmart Score of 68/100 (B-).
MDT
Strong Buy68
out of 100
Grade: B-
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.7%
Fair Value
$94.08
Current Price
$94.78
$0.70 premium
Margin of Safety
-18.0%
Fair Value
$12.34
Current Price
$12.93
$0.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 40.7% YoY
Generating 1.3B in free cash flow
17.1% revenue growth
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 36.9x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : MDT
The primary concerns for MDT are PEG Ratio, Altman Z-Score.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
MDT profiles as a value stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.87 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
MDT generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
MDT scores higher overall (68/100 vs 27/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?